Date: February 23, 2021
Time: 8:00am (PST), 11:00am (EST)
The analysis of serum free light chains (FLC) is now standard of care in the screening, diagnosis, and monitoring of patients suspected of/having multiple myeloma (MM) or other monoclonal gammopathies (MG). Recently, a new FLC immunoassay has become available from Diazyme. The objectives of our study were to analytically validate the Diazyme assay and to determine clinical interchangeability of two different FLC assays in patients with MG and in a presumed healthy population.
- Describe the serum free light chain assay and its role in the screening, diagnosis, and monitoring of patients with multiple myeloma
- List different methods by which free light chains are quantitated
- Identify issues which should be considered when switching free light chain assay
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.